Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Durect has reported that Pain Therapeutics, its licensee, has submitted an investigational new drug application to the FDA for an abuse-resistant opioid pain drug candidate based on its patented Oradur technology.
Subscribe to our email newsletter
This is said to be the third Oradur-based opioid drug candidate covered by Durect’s collaboration with Pain Therapeutics, for which King Pharmaceuticals holds the commercialization rights.
Pain Therapeutics and King Pharmaceuticals have stated that they expect to announce shortly the initiation of a clinical study with this new investigational drug candidate. This new drug candidate is the third Oradur-based opioid drug to enter development.
James Brown, CEO of Durect, said: “We are very pleased with the progress and speed with which Pain Therapeutics and King Pharmaceuticals are developing this series of four opioids licensed from us. This marks another milestone for our Oradur technology as a versatile platform that provides for the controlled delivery of pharmaceuticals that are commonly abused.”